4D Molecular Therapeutics (NASDAQ: FDMT) elevates CFO Kristian Humer to Principal Accounting Officer

Rhea-AI Filing Summary

4D Molecular Therapeutics, Inc. announced a leadership change in its finance function. On March 25, 2026, the Board appointed Kristian Humer as the company’s Principal Accounting Officer, effective immediately. He will hold this role in addition to serving as Chief Financial Officer and Principal Financial Officer.

Humer succeeds Ashoo Gupta in the Principal Accounting Officer role; Gupta remains Vice President, Finance and Controller. The filing highlights Humer’s prior experience as CFO at Foghorn Therapeutics and Viridian Therapeutics and his earlier senior investment banking roles at Citigroup focused on healthcare.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Appointment date: March 25, 2026 Age of appointee: 51 years

2 metrics

Appointment date March 25, 2026 Date Board appointed Principal Accounting Officer

Age of appointee 51 years Age of Kristian Humer at time of appointment

Key Terms

Principal Accounting Officer, Principal Financial Officer, Emerging growth company, Item 5.02, +1 more

5 terms

Principal Accounting Officer financial

"appointed Kristian Humer as the Company’s Principal Accounting Officer, effective immediately"

The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.

Principal Financial Officer financial

"has served as the Company’s Chief Financial Officer and Principal Financial Officer since November 2025"

The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.

Emerging growth company regulatory

"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Item 5.02 regulatory

"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers"

Nasdaq Global Select Market market

"Common Stock, $0.0001 par value per share | FDMT | Nasdaq Global Select Market"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

Understanding 8-K Material Events →

false000165064800016506482026-03-252026-03-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 25, 2026

4D Molecular Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39782	47-3506994
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
5858 Horton Street #455
Emeryville, California				94608
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 505-2680

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		FDMT		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 25, 2026, the Board of Directors of 4D Molecular Therapeutics, Inc. (the “Company”) appointed Kristian Humer as the Company’s Principal Accounting Officer, effective immediately. In this role, Mr. Humer succeeds Ashoo Gupta, who continues to serve as the Company’s Vice President, Finance and Controller.

Mr. Humer, age 51, has served as the Company’s Chief Financial Officer and Principal Financial Officer since November 2025. Mr. Humer previously served as the Chief Financial Officer at Foghorn Therapeutics, Inc., a biotechnology company, from April 2024 to November 2025. From July 2021 to September 2023, Mr. Humer served as Chief Financial Officer and Chief Business Officer at Viridian Therapeutics, Inc., a biotechnology company. From January 2010 to July 2021, Mr. Humer served in various roles at Citigroup Global Markets Inc., including most recently as Managing Director in the Healthcare Investment Banking Group from December 2016 to July 2021. Mr. Humer holds an MBA degree from Duke University’s Fuqua School of Business and a BA (Hons) degree in Accounting & Economics from the University of Reading.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			4D MOLECULAR THERAPEUTICS, INC.
Date:	March 30, 2026	By:	/s/David Kirn, M.D.
			David Kirn, M.D. President and Chief Executive Officer

FAQ

What leadership change did 4D Molecular Therapeutics (FDMT) disclose in this 8-K?

4D Molecular Therapeutics disclosed that its Board appointed Kristian Humer as Principal Accounting Officer effective March 25, 2026. He already serves as Chief Financial Officer and Principal Financial Officer, consolidating key finance and accounting responsibilities under a single executive leader.

Who is replacing whom as Principal Accounting Officer at 4D Molecular Therapeutics (FDMT)?

Kristian Humer is replacing Ashoo Gupta as Principal Accounting Officer at 4D Molecular Therapeutics. Gupta will continue with the company in her existing position as Vice President, Finance and Controller, maintaining continuity in the broader finance organization while shifting the designated accounting officer role.

What is Kristian Humer’s current role at 4D Molecular Therapeutics (FDMT)?

Kristian Humer serves as Chief Financial Officer and Principal Financial Officer and has now been appointed Principal Accounting Officer. This means he oversees the company’s overall financial management and is also designated as the primary officer responsible for accounting oversight and related SEC reporting functions.

What prior experience does Kristian Humer bring to 4D Molecular Therapeutics (FDMT)?

Kristian Humer previously served as Chief Financial Officer at Foghorn Therapeutics and as Chief Financial Officer and Chief Business Officer at Viridian Therapeutics. Before those roles, he spent over a decade at Citigroup Global Markets, most recently as Managing Director in the Healthcare Investment Banking Group.

When did the Board of 4D Molecular Therapeutics (FDMT) approve this officer change?

The Board of 4D Molecular Therapeutics approved the appointment of Kristian Humer as Principal Accounting Officer on March 25, 2026. The change was effective immediately as of that date, and the company later recorded the event in its current report signed by President and Chief Executive Officer David Kirn.

Does Ashoo Gupta remain with 4D Molecular Therapeutics (FDMT) after this change?

Yes. Although Ashoo Gupta is no longer designated as Principal Accounting Officer, she continues as Vice President, Finance and Controller. This preserves leadership continuity in the finance team while reassigning the formal Principal Accounting Officer title to Chief Financial Officer and Principal Financial Officer Kristian Humer.

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 25.5 KB